Innovita Biological Technology Co. Ltd. A (688253) - Total Assets
Based on the latest financial reports, Innovita Biological Technology Co. Ltd. A (688253) holds total assets worth CN¥2.23 Billion CNY (≈ $326.60 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688253 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Innovita Biological Technology Co. Ltd. A - Total Assets Trend (2020–2025)
This chart illustrates how Innovita Biological Technology Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Check Innovita Biological Technology Co. Ltd. (688253) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Innovita Biological Technology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Innovita Biological Technology Co. Ltd. A's total assets of CN¥2.23 Billion consist of 89.1% current assets and 10.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.9% |
| Accounts Receivable | CN¥12.00 Million | 0.5% |
| Inventory | CN¥57.18 Million | 2.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥18.32 Million | 0.8% |
| Goodwill | CN¥3.64 Million | 0.2% |
Asset Composition Trend (2020–2025)
This chart illustrates how Innovita Biological Technology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Innovita Biological Technology Co. Ltd. .
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innovita Biological Technology Co. Ltd. A's current assets represent 89.1% of total assets in 2025, an increase from 87.0% in 2020.
- Cash Position: Cash and equivalents constituted 24.9% of total assets in 2025, down from 61.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 2.5% of total assets.
Innovita Biological Technology Co. Ltd. A Competitors by Total Assets
Key competitors of Innovita Biological Technology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Innovita Biological Technology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.58 | 10.21 | 14.72 |
| Quick Ratio | 15.22 | 9.96 | 14.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.83 Billion | CN¥1.86 Billion | CN¥1.55 Billion |
Innovita Biological Technology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Innovita Biological Technology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.31 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | CN¥2.28 Billion |
| Market Capitalization | $1.18 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Innovita Biological Technology Co. Ltd. A's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Innovita Biological Technology Co. Ltd. A's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Innovita Biological Technology Co. Ltd. A (2020–2025)
The table below shows the annual total assets of Innovita Biological Technology Co. Ltd. A from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.28 Billion ≈ $332.96 Million |
+2.84% |
| 2024-12-31 | CN¥2.21 Billion ≈ $323.75 Million |
+7.11% |
| 2023-12-31 | CN¥2.07 Billion ≈ $302.27 Million |
+6.34% |
| 2022-12-31 | CN¥1.94 Billion ≈ $284.26 Million |
+143.47% |
| 2021-12-31 | CN¥797.87 Million ≈ $116.75 Million |
+2.02% |
| 2020-12-31 | CN¥782.09 Million ≈ $114.44 Million |
-- |
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.